second generation cephalosporin
PreclinicalSmall molecule
second generation cephalosporin is one of 29 small molecule programs targeting Achalasia. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Innohep
Alnylam PharmaceuticalsPreclinical
Jakafi
IncytePreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Tylenol
KKenvue Brands
Preclinical
Cancidas
FFresenius Kabi Oncology Ltd.
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Zhongshan Hospital